Concepts (307)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Scoliosis | 10 | 2019 | 45 | 5.96 | Why? |
| Physical and Rehabilitation Medicine | 16 | 2021 | 469 | 5.37 | Why? |
| Rehabilitation | 11 | 2020 | 386 | 5.28 | Why? |
| Braces | 6 | 2019 | 14 | 2.74 | Why? |
| Rehabilitation Research | 3 | 2021 | 44 | 2.24 | Why? |
| Spinal Curvatures | 3 | 2017 | 28 | 2.06 | Why? |
| Low Back Pain | 4 | 2021 | 190 | 2.00 | Why? |
| Evidence-Based Medicine | 10 | 2021 | 3228 | 1.94 | Why? |
| Databases, Bibliographic | 2 | 2018 | 182 | 1.35 | Why? |
| Postural Balance | 3 | 2017 | 144 | 1.33 | Why? |
| Disabled Persons | 6 | 2020 | 1152 | 1.22 | Why? |
| Spinal Diseases | 2 | 2020 | 238 | 1.21 | Why? |
| Exercise Therapy | 4 | 2020 | 976 | 1.20 | Why? |
| Review Literature as Topic | 2 | 2018 | 387 | 1.14 | Why? |
| Vasodilator Agents | 2 | 2019 | 344 | 1.07 | Why? |
| Pain Measurement | 5 | 2019 | 533 | 1.01 | Why? |
| Kyphosis | 2 | 2019 | 18 | 0.96 | Why? |
| Periodicals as Topic | 3 | 2021 | 1492 | 0.93 | Why? |
| Scleroderma, Systemic | 3 | 2019 | 583 | 0.90 | Why? |
| HLA Antigens | 2 | 2017 | 830 | 0.87 | Why? |
| Orthotic Devices | 2 | 2017 | 9 | 0.87 | Why? |
| Musculoskeletal Diseases | 2 | 2018 | 646 | 0.83 | Why? |
| Bibliometrics | 2 | 2018 | 731 | 0.81 | Why? |
| Iloprost | 1 | 2019 | 38 | 0.78 | Why? |
| Growth | 1 | 2018 | 19 | 0.74 | Why? |
| Whiplash Injuries | 1 | 2017 | 6 | 0.73 | Why? |
| Blogging | 1 | 2018 | 44 | 0.71 | Why? |
| Eosinophilic Granuloma | 1 | 2017 | 3 | 0.71 | Why? |
| Disability Evaluation | 3 | 2019 | 671 | 0.70 | Why? |
| Peripheral Vascular Diseases | 1 | 2019 | 133 | 0.70 | Why? |
| Craniofacial Abnormalities | 1 | 2017 | 33 | 0.69 | Why? |
| Cancer Pain | 1 | 2018 | 91 | 0.67 | Why? |
| Organizations, Nonprofit | 1 | 2018 | 87 | 0.66 | Why? |
| Stroke Rehabilitation | 2 | 2017 | 299 | 0.64 | Why? |
| Paralysis | 1 | 2017 | 92 | 0.63 | Why? |
| Thoracic Vertebrae | 1 | 2017 | 97 | 0.63 | Why? |
| Program Evaluation | 2 | 2021 | 1929 | 0.58 | Why? |
| Chronic Pain | 3 | 2018 | 736 | 0.57 | Why? |
| Raynaud Disease | 1 | 2015 | 86 | 0.56 | Why? |
| Forecasting | 4 | 2018 | 4492 | 0.55 | Why? |
| Parkinson Disease | 2 | 2017 | 1414 | 0.54 | Why? |
| Physical Therapy Modalities | 8 | 2019 | 1090 | 0.53 | Why? |
| Drug Hypersensitivity | 2 | 2017 | 401 | 0.53 | Why? |
| Advisory Committees | 2 | 2018 | 1418 | 0.52 | Why? |
| Robotics | 2 | 2017 | 528 | 0.52 | Why? |
| Search Engine | 1 | 2021 | 628 | 0.51 | Why? |
| Checklist | 1 | 2019 | 714 | 0.51 | Why? |
| Conservative Treatment | 1 | 2016 | 349 | 0.50 | Why? |
| World Health Organization | 4 | 2021 | 4213 | 0.48 | Why? |
| Tetrazoles | 1 | 2015 | 262 | 0.48 | Why? |
| Hand | 1 | 2017 | 449 | 0.47 | Why? |
| Genetic Predisposition to Disease | 2 | 2017 | 4027 | 0.47 | Why? |
| Transcription Factors | 1 | 2018 | 784 | 0.47 | Why? |
| Video Games | 1 | 2016 | 270 | 0.47 | Why? |
| Multiple Organ Failure | 1 | 2021 | 1724 | 0.43 | Why? |
| Overweight | 1 | 2017 | 916 | 0.42 | Why? |
| Health Services Needs and Demand | 3 | 2020 | 3419 | 0.42 | Why? |
| Patient Satisfaction | 2 | 2020 | 2517 | 0.41 | Why? |
| Evidence-Based Practice | 5 | 2019 | 693 | 0.40 | Why? |
| Decision Making | 2 | 2021 | 3132 | 0.38 | Why? |
| Humans | 82 | 2021 | 930598 | 0.37 | Why? |
| Quality of Life | 3 | 2019 | 9820 | 0.37 | Why? |
| Health Policy | 3 | 2018 | 6242 | 0.36 | Why? |
| Ambulatory Care | 3 | 2020 | 4947 | 0.35 | Why? |
| Etanercept | 3 | 2019 | 162 | 0.35 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.34 | Why? |
| Back Pain | 2 | 2019 | 115 | 0.34 | Why? |
| Pharmacogenetics | 3 | 2017 | 222 | 0.34 | Why? |
| Rehabilitation Centers | 2 | 2020 | 252 | 0.34 | Why? |
| Outpatients | 1 | 2020 | 3417 | 0.33 | Why? |
| Health Promotion | 2 | 2018 | 2020 | 0.32 | Why? |
| Upper Extremity | 2 | 2019 | 193 | 0.30 | Why? |
| Italy | 12 | 2020 | 38444 | 0.29 | Why? |
| Surveys and Questionnaires | 7 | 2019 | 43792 | 0.29 | Why? |
| Information Dissemination | 2 | 2018 | 2986 | 0.29 | Why? |
| Research Design | 2 | 2021 | 5830 | 0.29 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.27 | Why? |
| International Cooperation | 1 | 2018 | 3436 | 0.27 | Why? |
| Betacoronavirus | 10 | 2020 | 204454 | 0.25 | Why? |
| T-Lymphocytes, Regulatory | 3 | 2017 | 698 | 0.25 | Why? |
| Pilot Projects | 3 | 2019 | 5182 | 0.24 | Why? |
| T-Lymphocyte Subsets | 3 | 2017 | 1387 | 0.23 | Why? |
| Female | 38 | 2020 | 380317 | 0.23 | Why? |
| Male | 35 | 2020 | 367725 | 0.22 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.21 | Why? |
| Pneumonia, Viral | 12 | 2020 | 243684 | 0.21 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.21 | Why? |
| Pandemics | 17 | 2021 | 389249 | 0.21 | Why? |
| International Classification of Functioning, Disability and Health | 1 | 2019 | 11 | 0.20 | Why? |
| Professional Practice | 3 | 2018 | 322 | 0.20 | Why? |
| Social Theory | 1 | 2019 | 20 | 0.20 | Why? |
| Coronavirus Infections | 11 | 2020 | 253789 | 0.20 | Why? |
| Adolescent | 14 | 2019 | 86841 | 0.20 | Why? |
| Hand Joints | 1 | 2019 | 31 | 0.19 | Why? |
| Spinal Dysraphism | 1 | 2018 | 19 | 0.19 | Why? |
| Brachial Plexus | 1 | 2019 | 28 | 0.19 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.19 | Why? |
| Manipulation, Osteopathic | 1 | 2018 | 10 | 0.19 | Why? |
| Physiatrists | 1 | 2019 | 35 | 0.19 | Why? |
| Functional Laterality | 1 | 2018 | 57 | 0.18 | Why? |
| Telemedicine | 2 | 2020 | 25032 | 0.18 | Why? |
| Treatment Outcome | 9 | 2020 | 51732 | 0.18 | Why? |
| Gait | 2 | 2016 | 137 | 0.18 | Why? |
| Curettage | 1 | 2017 | 8 | 0.18 | Why? |
| Fractures, Spontaneous | 1 | 2017 | 15 | 0.17 | Why? |
| Infliximab | 2 | 2019 | 502 | 0.17 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.17 | Why? |
| Behavioral Medicine | 1 | 2019 | 84 | 0.17 | Why? |
| Carbamazepine | 1 | 2017 | 34 | 0.17 | Why? |
| Acute Pain | 1 | 2018 | 73 | 0.17 | Why? |
| Allopurinol | 1 | 2017 | 59 | 0.16 | Why? |
| Trauma Severity Indices | 1 | 2017 | 176 | 0.16 | Why? |
| Visual Analog Scale | 1 | 2017 | 151 | 0.16 | Why? |
| Journal Impact Factor | 1 | 2018 | 134 | 0.16 | Why? |
| Dideoxynucleosides | 1 | 2017 | 92 | 0.16 | Why? |
| Pelvis | 1 | 2017 | 125 | 0.16 | Why? |
| Observer Variation | 1 | 2019 | 622 | 0.16 | Why? |
| Intention to Treat Analysis | 1 | 2018 | 673 | 0.16 | Why? |
| Antirheumatic Agents | 4 | 2019 | 3023 | 0.16 | Why? |
| Communicable Disease Control | 3 | 2021 | 29620 | 0.16 | Why? |
| HLA-G Antigens | 1 | 2016 | 48 | 0.16 | Why? |
| Osteoarthritis | 1 | 2019 | 205 | 0.16 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.16 | Why? |
| Neck Pain | 1 | 2017 | 126 | 0.15 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.15 | Why? |
| Lumbar Vertebrae | 1 | 2017 | 196 | 0.15 | Why? |
| Tobacco Smoking | 1 | 2020 | 349 | 0.15 | Why? |
| Controlled Before-After Studies | 1 | 2015 | 51 | 0.15 | Why? |
| Subacute Care | 1 | 2020 | 315 | 0.15 | Why? |
| Movement | 1 | 2018 | 232 | 0.15 | Why? |
| Anorexia Nervosa | 1 | 2017 | 103 | 0.15 | Why? |
| Spinal Fractures | 1 | 2017 | 124 | 0.15 | Why? |
| Neck | 1 | 2017 | 307 | 0.14 | Why? |
| Adalimumab | 1 | 2019 | 389 | 0.14 | Why? |
| Tumor Necrosis Factor-alpha | 4 | 2019 | 2483 | 0.14 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2017 | 309 | 0.14 | Why? |
| Cognition Disorders | 1 | 2020 | 574 | 0.14 | Why? |
| Research Report | 1 | 2019 | 376 | 0.14 | Why? |
| Europe | 4 | 2020 | 12702 | 0.14 | Why? |
| Arthritis, Juvenile | 1 | 2017 | 191 | 0.14 | Why? |
| Acceleration | 1 | 2014 | 26 | 0.14 | Why? |
| Spondylitis, Ankylosing | 1 | 2017 | 231 | 0.14 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.14 | Why? |
| Reproducibility of Results | 4 | 2019 | 11304 | 0.14 | Why? |
| Global Health | 4 | 2021 | 13911 | 0.14 | Why? |
| Alleles | 2 | 2017 | 1557 | 0.14 | Why? |
| Immune System Diseases | 1 | 2019 | 410 | 0.14 | Why? |
| United Nations | 1 | 2017 | 367 | 0.14 | Why? |
| Prospective Studies | 6 | 2020 | 43301 | 0.14 | Why? |
| Spine | 1 | 2017 | 292 | 0.13 | Why? |
| Middle Aged | 19 | 2020 | 270681 | 0.13 | Why? |
| Aged | 16 | 2020 | 215776 | 0.13 | Why? |
| Cell Differentiation | 2 | 2018 | 1338 | 0.13 | Why? |
| Child | 8 | 2019 | 70012 | 0.13 | Why? |
| Cross-Sectional Studies | 8 | 2020 | 53120 | 0.13 | Why? |
| Regeneration | 1 | 2017 | 429 | 0.13 | Why? |
| Respiratory Therapy | 1 | 2020 | 918 | 0.13 | Why? |
| Practice Guidelines as Topic | 4 | 2018 | 15421 | 0.13 | Why? |
| Patient Outcome Assessment | 1 | 2017 | 707 | 0.12 | Why? |
| Brain Injuries | 1 | 2017 | 374 | 0.12 | Why? |
| Single-Blind Method | 1 | 2016 | 1283 | 0.12 | Why? |
| Neoplasms | 2 | 2018 | 17251 | 0.11 | Why? |
| Cohort Studies | 4 | 2020 | 36005 | 0.11 | Why? |
| Running | 1 | 2014 | 153 | 0.11 | Why? |
| Adult | 14 | 2021 | 244371 | 0.11 | Why? |
| Self Efficacy | 1 | 2018 | 717 | 0.11 | Why? |
| Program Development | 1 | 2018 | 1089 | 0.11 | Why? |
| Accidental Falls | 1 | 2016 | 448 | 0.11 | Why? |
| Anticonvulsants | 1 | 2017 | 634 | 0.11 | Why? |
| Delivery of Health Care | 1 | 2018 | 15909 | 0.11 | Why? |
| Arthritis, Psoriatic | 1 | 2017 | 625 | 0.11 | Why? |
| Attention | 1 | 2014 | 335 | 0.11 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.11 | Why? |
| Tertiary Care Centers | 2 | 2019 | 8248 | 0.11 | Why? |
| Feasibility Studies | 1 | 2020 | 3467 | 0.11 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.10 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.10 | Why? |
| Health Services for the Aged | 1 | 2017 | 602 | 0.10 | Why? |
| Allergens | 1 | 2016 | 728 | 0.10 | Why? |
| Cyclophosphamide | 1 | 2012 | 387 | 0.10 | Why? |
| Policy Making | 1 | 2017 | 829 | 0.10 | Why? |
| European Union | 3 | 2018 | 565 | 0.10 | Why? |
| Propensity Score | 1 | 2018 | 2690 | 0.10 | Why? |
| Respiratory Tract Diseases | 1 | 2018 | 1061 | 0.10 | Why? |
| Pain Management | 1 | 2018 | 854 | 0.10 | Why? |
| Walking | 1 | 2014 | 442 | 0.10 | Why? |
| Aged, 80 and over | 7 | 2019 | 88759 | 0.10 | Why? |
| Radiography | 1 | 2017 | 1576 | 0.09 | Why? |
| Cognition | 1 | 2017 | 1394 | 0.09 | Why? |
| Intellectual Disability | 1 | 2014 | 391 | 0.09 | Why? |
| Qualitative Research | 1 | 2020 | 4337 | 0.09 | Why? |
| Life Style | 1 | 2020 | 2708 | 0.08 | Why? |
| Immunomodulation | 1 | 2016 | 1472 | 0.08 | Why? |
| Immunotherapy, Adoptive | 1 | 2012 | 524 | 0.08 | Why? |
| Referral and Consultation | 2 | 2020 | 4816 | 0.08 | Why? |
| Equipment Design | 1 | 2018 | 3095 | 0.08 | Why? |
| Organizational Innovation | 1 | 2017 | 2468 | 0.08 | Why? |
| Chronic Disease | 2 | 2018 | 5139 | 0.08 | Why? |
| Enzyme Inhibitors | 1 | 2017 | 1881 | 0.08 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.08 | Why? |
| Hypersensitivity | 1 | 2016 | 1137 | 0.08 | Why? |
| Practice Patterns, Physicians' | 3 | 2019 | 4927 | 0.07 | Why? |
| Th17 Cells | 1 | 2011 | 657 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2019 | 1996 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.07 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.07 | Why? |
| Long-Term Care | 1 | 2017 | 2047 | 0.07 | Why? |
| Child, Preschool | 3 | 2018 | 36283 | 0.07 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.07 | Why? |
| Hemoglobinuria, Paroxysmal | 1 | 2005 | 116 | 0.07 | Why? |
| Vitamin D | 1 | 2019 | 2904 | 0.07 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.06 | Why? |
| Psoriasis | 1 | 2017 | 1739 | 0.06 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.06 | Why? |
| Delphi Technique | 2 | 2018 | 1257 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.06 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.06 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2017 | 5837 | 0.06 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.06 | Why? |
| Aging | 1 | 2017 | 3581 | 0.05 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.05 | Why? |
| Protein Isoforms | 2 | 2016 | 347 | 0.05 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.05 | Why? |
| Early Ambulation | 1 | 2020 | 102 | 0.05 | Why? |
| Palpation | 1 | 2019 | 16 | 0.05 | Why? |
| Mental Status and Dementia Tests | 1 | 2020 | 208 | 0.05 | Why? |
| Severity of Illness Index | 2 | 2017 | 48226 | 0.05 | Why? |
| Attitude of Health Personnel | 1 | 2017 | 4741 | 0.05 | Why? |
| Recovery of Function | 2 | 2020 | 2461 | 0.05 | Why? |
| Range of Motion, Articular | 1 | 2019 | 168 | 0.04 | Why? |
| Hand Strength | 1 | 2019 | 202 | 0.04 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.04 | Why? |
| Young Adult | 5 | 2019 | 93724 | 0.04 | Why? |
| Medical History Taking | 1 | 2019 | 350 | 0.04 | Why? |
| Social Media | 1 | 2018 | 5798 | 0.04 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.04 | Why? |
| Muscle Spasticity | 1 | 2017 | 117 | 0.04 | Why? |
| Factor Analysis, Statistical | 1 | 2018 | 538 | 0.04 | Why? |
| Child Development Disorders, Pervasive | 1 | 2014 | 17 | 0.04 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.03 | Why? |
| Stroke | 1 | 2017 | 8839 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2018 | 11497 | 0.03 | Why? |
| Physical Examination | 1 | 2019 | 755 | 0.03 | Why? |
| Tumor Escape | 1 | 2012 | 36 | 0.03 | Why? |
| Opportunistic Infections | 1 | 2019 | 602 | 0.03 | Why? |
| CD28 Antigens | 1 | 2012 | 39 | 0.03 | Why? |
| CD8 Antigens | 1 | 2012 | 72 | 0.03 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.03 | Why? |
| Animals | 2 | 2019 | 78931 | 0.03 | Why? |
| Reference Values | 1 | 2014 | 795 | 0.03 | Why? |
| Cell Proliferation | 2 | 2011 | 1973 | 0.03 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.03 | Why? |
| Muscle, Skeletal | 1 | 2017 | 915 | 0.03 | Why? |
| Psychometrics | 1 | 2018 | 1269 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.03 | Why? |
| Soccer | 1 | 2014 | 259 | 0.02 | Why? |
| Flow Cytometry | 2 | 2011 | 2393 | 0.02 | Why? |
| Immune System | 1 | 2019 | 1479 | 0.02 | Why? |
| Physician's Role | 1 | 2018 | 853 | 0.02 | Why? |
| Necrosis | 1 | 2012 | 532 | 0.02 | Why? |
| Rhinitis, Allergic | 1 | 2016 | 704 | 0.02 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 1454 | 0.02 | Why? |
| Dermatitis, Atopic | 1 | 2016 | 714 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2005 | 6670 | 0.02 | Why? |
| Health Personnel | 1 | 2018 | 29646 | 0.02 | Why? |
| Statistics, Nonparametric | 1 | 2011 | 1008 | 0.02 | Why? |
| Immune Tolerance | 1 | 2012 | 608 | 0.02 | Why? |
| Dietary Supplements | 1 | 2019 | 2251 | 0.02 | Why? |
| Glycosylphosphatidylinositols | 1 | 2005 | 6 | 0.02 | Why? |
| Immunophenotyping | 1 | 2011 | 1290 | 0.02 | Why? |
| Vitamin D Deficiency | 1 | 2019 | 1782 | 0.02 | Why? |
| Quality Improvement | 1 | 2017 | 2435 | 0.02 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.02 | Why? |
| Internationality | 1 | 2017 | 3297 | 0.02 | Why? |
| CD3 Complex | 1 | 2005 | 237 | 0.02 | Why? |
| Fluorescent Antibody Technique, Indirect | 1 | 2005 | 393 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.02 | Why? |
| Comorbidity | 2 | 2019 | 34796 | 0.02 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.02 | Why? |
| Family | 1 | 2017 | 2909 | 0.02 | Why? |
| Social Support | 1 | 2017 | 3183 | 0.02 | Why? |
| Immunologic Factors | 1 | 2019 | 4206 | 0.02 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| HIV-1 | 1 | 2017 | 3365 | 0.01 | Why? |
| Hematopoietic Stem Cells | 1 | 2005 | 321 | 0.01 | Why? |
| Caregivers | 1 | 2017 | 3112 | 0.01 | Why? |
| Apoptosis | 1 | 2012 | 2335 | 0.01 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 3832 | 0.01 | Why? |
| Cells, Cultured | 1 | 2012 | 5835 | 0.01 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.01 | Why? |
| Ligands | 1 | 2005 | 1300 | 0.01 | Why? |
| Cell Membrane | 1 | 2005 | 743 | 0.01 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.01 | Why? |
| Asthma | 1 | 2016 | 4383 | 0.01 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.01 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.01 | Why? |
| Sex Factors | 1 | 2014 | 11014 | 0.01 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2011 | 4545 | 0.01 | Why? |
| Leukocytes, Mononuclear | 1 | 2005 | 2115 | 0.01 | Why? |
| Lymphocyte Activation | 1 | 2005 | 2742 | 0.01 | Why? |
| Interferon-gamma | 1 | 2005 | 2711 | 0.01 | Why? |
| Killer Cells, Natural | 1 | 2005 | 2093 | 0.01 | Why? |
| Pregnancy | 1 | 2016 | 23879 | 0.01 | Why? |
| Genotype | 1 | 2005 | 4697 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Cytokines | 1 | 2011 | 15010 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2005 | 8041 | 0.00 | Why? |